Manufacturing Issues Delay Half Of Pending BLAs, CBER’s Yetter Says
• By The Pink Sheet
Half of the active pending BLAs at the Office of Therapeutics Research & Review as of Jan. 1 have manufacturing concerns, Center for Biologics Evaluation & Research Associate Director-Review Management Robert Yetter, PhD, said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
